Answers are grounded in this paper and cite their sources.
Background Pulmonary fibrosis is a devastating disease with limited therapeutic options. Macrophage migration inhibitory factor (MIF) has been implicated in fibrogenesis, but its metabolic regulatory mechanisms remain unclear. Methods We established a bleomycin (BLM)-induced pulmonary fibrosis mouse model and TGF-β1-stimulated primary lung fibroblasts. MIF was inhibited in vivo using a MIF-targeting shRNA lentivirus (shMIF) or the pharmacological inhibitor (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1), and in vitro using ISO-1. Fibrotic progression, aerobic glycolysis, PHD expression, HIF-1α protein levels, and succinate accumulation were assessed. Results MIF inhibition reduced aerobic glycolytic flux, as evidenced by decreased ECAR and lactate levels. Mechanistically, MIF downregulated PHD1/2 expression, increased HIF-1α protein levels, and promoted succinate accumulation under normoxic conditions, accompanied by enhanced fibrogenic responses. Conclusion These findings suggest that MIF promotes pulmonary fibrosis in association with the PISD-succinate-HIF-1α axis, potentially involving reduced PHD expression and increased HIF-1α protein levels. Rescue experiments further suggest that MIF promotes fibroblast activation at least in part through glycolysis-dependent mechanisms.
No takes yet. Share an insight, caveat, or question.
Lan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: